NCT00077597View on ClinicalTrials.gov

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Anemia
Interventions
DRUG

epoetin

3 times a week iv, as prescribed.

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

0.4 micrograms/kg iv (starting dose) once every 2 weeks

Trial Locations (59)

1011

Lausanne

2193

Johannesburg

5021

Bergen

10128

New York

10700

Bangkok

11501

Mineola

18354

Nikaia

30342

Atlanta

30901

Augusta

39008

Santander

43606

Toledo

48013

Bilbao

50200

Chiang Mai

54629

Thessaloniki

65185

Karlstad

68100

Alexandroupoli

70112

New Orleans

77054

Houston

80260

Lakewood

95616

Davis

123182

Moscow

125101

Moscow

129110

Moscow

195067

Saint Petersburg

197089

Saint Petersburg

02115

Boston

01107

Springfield

48202-2689

Detroit

05401

Burlington

23507-1901

Norfolk

81050-090

Curitiba

14025-170

Ribeirão Preto

01307-001

São Paulo

04039-000

São Paulo

T2N 2T9

Calgary

V5Z 1M9

Vancouver

R3A 1R9

Winnipeg

A1B 3V6

St. John's

K7L 3N6

Kingston

N6A 5A5

London

M5G 2C4

Toronto

H3A 1A1

Montreal

S7K 1N4

Saskatoon

460 63

Liberec

169 00

Prague

401 13

Ústí nad Labem

41 110

Larissa

0407

Oslo

80-211

Gdansk

81-519

Gdynia

31-501

Krakow

90-153

Lodz

60-355

Poznan

70-111

Szczecin

05-200

Wołomin

50-417

Wroclaw

Unknown

Soweto

Bangkok

Chon Buri

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00077597 - A Study of Mircera for the Treatment of Anemia in Dialysis Patients | Biotech Hunter | Biotech Hunter